{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:42:17Z","timestamp":1791600137822,"version":"4.3.4"},"reference-count":186,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105214","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:45:29Z","timestamp":1770943529000},"page":"105214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting lncRNA-mediated networks to overcome doxorubicin resistance in cancer"],"prefix":"10.1016","volume":"221","author":[{"given":"Mengru","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyin","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA a cancer journal clinicians"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105214_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA a cancer journal clinicians"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105214_bib3","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","article-title":"Comparative analysis of cancer statistics in China and the United States in 2024","volume":"137","author":"Wu","year":"2024","journal-title":"Chin. Med. J."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105214_bib5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","article-title":"Tumor cell metabolism: cancer's Achilles' heel","volume":"13","author":"Kroemer","year":"2008","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s13346-024-01648-0","article-title":"A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer","volume":"15","author":"Bisht","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.7150\/ijbs.65258","article-title":"Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death","volume":"18","author":"Kong","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105214_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031912","article-title":"Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity","volume":"23","author":"Wu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105214_bib11","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-019-03827-0","article-title":"Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain","volume":"84","author":"El-Agamy","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.critrevonc.2026.105214_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101205","article-title":"Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming","volume":"93","author":"Mattioli","year":"2023","journal-title":"Mol. Asp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","article-title":"Clinical pharmacokinetics of doxorubicin","volume":"15","author":"Speth","year":"1988","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell death Dis."},{"key":"10.1016\/j.critrevonc.2026.105214_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102818","article-title":"Targeting autophagy in doxorubicin-induced cardiotoxicity: A comprehensive review of scientific landscapes and therapeutic innovations","volume":"110","author":"Wang","year":"2025","journal-title":"Ageing Res. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.tig.2015.03.007","article-title":"The Landscape of long noncoding RNA classification","volume":"31","author":"St Laurent","year":"2015","journal-title":"Trends genetics TIG"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105214_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cell.2018.01.011","article-title":"Functional Classification and Experimental Dissection of Long Noncoding RNAs","volume":"172","author":"Kopp","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac205","article-title":"Secondary structure prediction of long noncoding RNA: review and experimental comparison of existing approaches","volume":"23","author":"Bugnon","year":"2022","journal-title":"Brief. Bioinforma."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105214_bib21","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.molcel.2022.05.027","article-title":"Integrated lncRNA function upon genomic and epigenomic regulation","volume":"82","author":"Herman","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2026.105214_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biochi.2015.03.001","article-title":"Long noncoding RNA turnover","volume":"117","author":"Yoon","year":"2015","journal-title":"Biochimie"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib23","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2023.5276","article-title":"The role of long noncoding RNA H19 in gynecological pathologies: Insights into gene regulation and immune modulation (Review)","volume":"52","author":"Xin","year":"2023","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105214_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cca.2019.08.031","article-title":"Long noncoding RNA OIP5-AS1 in cancer","volume":"499","author":"Li","year":"2019","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/EBC20200032","article-title":"Non-coding RNA in cancer","volume":"65","author":"Yan","year":"2021","journal-title":"Essays Biochem."},{"key":"10.1016\/j.critrevonc.2026.105214_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cca.2018.05.010","article-title":"Long noncoding RNA CYTOR in cancer: A TCGA data review","volume":"483","author":"Liang","year":"2018","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12943-021-01455-y","article-title":"Long non-coding RNA NORAD\/miR-224-3p\/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of \u03b2-catenin","volume":"20","author":"Jia","year":"2021","journal-title":"Mol. Cancer"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2026.105214_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2015.12.017","article-title":"Noncoding RNA NORAD Regulates Genomic Stability by Sequestering PUMILIO Proteins","volume":"164","author":"Lee","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105214_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155657","article-title":"LncRNA MEG3 suppresses PI3K\/AKT\/mTOR signalling pathway to enhance autophagy and inhibit inflammation in TNF-\u03b1-treated keratinocytes and psoriatic mice","volume":"148","author":"Tang","year":"2021","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1186\/s12885-022-09833-5","article-title":"LncRNA NDRG1 aggravates osteosarcoma progression and regulates the PI3K\/AKT pathway by sponging miR-96-5p","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib31","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1007\/s10528-023-10592-6","article-title":"LncRNA MALAT1 Expression Regulates Breast Cancer Progression via PI3K\/AKT\/mTOR Pathway Modulation","volume":"62","author":"Naveed","year":"2024","journal-title":"Biochem. Genet."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105214_bib32","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/1120009X.2022.2082348","article-title":"LncRNA-IQCH-AS1 sensitizes thyroid cancer cells to doxorubicin via modulating the miR-196a-5p\/PPP2R1B signalling pathway","volume":"35","author":"Fei","year":"2023","journal-title":"J. Chemother. (Florence Italy)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13045-021-01194-z","article-title":"A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1186\/s13019-024-03129-4","article-title":"LncRNA CASC9 facilitates papillary thyroid cancer development and doxorubicin resistance via miR-28-3p\/BCL-2 axis and PI3K\/AKT signaling pathway","volume":"19","author":"Yu","year":"2024","journal-title":"J. Cardiothorac. Surg."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cac2.12108","article-title":"LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer","volume":"41","author":"Tan","year":"2021","journal-title":"Cancer communications (London England)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-024-01591-0","article-title":"LncRNA-encoded peptides in cancer","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105214_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106418","article-title":"Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy","volume":"184","author":"Hashemi","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105214_bib38","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","article-title":"Long Noncoding RNA and Cancer: A New Paradigm","volume":"77","author":"Bhan","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab504","article-title":"Tumor immune microenvironment lncRNAs","volume":"23","author":"Park","year":"2022","journal-title":"Brief. Bioinforma."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10238-025-01618-x","article-title":"Role of exercise on the reduction of cancer development: a mechanistic review from the lncRNA point of view","volume":"25","author":"Liu","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11010-020-03904-6","article-title":"LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p\/Nova1 axis","volume":"476","author":"Cao","year":"2021","journal-title":"Mol. Cell. Biochem."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105214_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23119","article-title":"The lncARSR\/PTEN\/Akt\/nuclear factor-kappa B feedback regulatory loop contributes to doxorubicin resistance in hepatocellular carcinoma","volume":"36","author":"Li","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4093\/dmj.2021.0306","article-title":"N6-Methyladenosine Methyltransferase METTL3 Alleviates Diabetes-Induced Testicular Damage through Modulating TUG1\/Clusterin Axis","volume":"47","author":"Tian","year":"2023","journal-title":"Diabetes Metab. J."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/08923973.2022.2054428","article-title":"Up-regulation of LncRNA UCA1 by TGF-\u03b2 promotes doxorubicin resistance in breast cancer cells","volume":"44","author":"Wo","year":"2022","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105214_bib45","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/1440-1681.13307","article-title":"LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN","volume":"47","author":"Zhang","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"42","key":"10.1016\/j.critrevonc.2026.105214_bib46","doi-asserted-by":"crossref","first-page":"71881","DOI":"10.18632\/oncotarget.17985","article-title":"LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1","volume":"8","author":"Kun-Peng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105214_bib47","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.biopha.2018.07.003","article-title":"Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a\/MCL1 axis","volume":"106","author":"Zhou","year":"2018","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105214_bib48","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/tox.23501","article-title":"LncRNA PVT1 contributes to invasion and doxorubicin resistance of bladder cancer cells through promoting MDM2 expression and AURKB-mediated p53 ubiquitination","volume":"37","author":"Jiang","year":"2022","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.critrevonc.2026.105214_bib49","article-title":"LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p","volume":"129","author":"Wang","year":"2020","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105214_bib50","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/iub.2075","article-title":"LncRNA LOXL1-AS1\/miR-let-7a-5p\/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells","volume":"71","author":"Bai","year":"2019","journal-title":"IUBMB life"},{"key":"10.1016\/j.critrevonc.2026.105214_bib51","article-title":"Targeting the lncRNA DUXAP8\/miR-29a\/PIK3CA Network Restores Doxorubicin Chemosensitivity via PI3K-AKT-mTOR Signaling and Synergizes With Inotuzumab Ozogamicin in Chemotherapy-Resistant B-Cell Acute Lymphoblastic Leukemia","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105214_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123832","article-title":"METTL3-mediated TUG1 regulation of miR-9 in doxorubicin resistance in HCC","volume":"378","author":"Li","year":"2025","journal-title":"Life Sci."},{"issue":"6 2","key":"10.1016\/j.critrevonc.2026.105214_bib53","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/j.bj.2020.11.002","article-title":"LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570-3p","volume":"44","author":"Yue","year":"2021","journal-title":"Biomed. J."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1590\/1806-9282.20210966","article-title":"Long non-coding RNA HOTAIR induces the PI3K\/AKT\/mTOR signaling pathway in breast cancer cells","volume":"68","author":"Sadeghalvad","year":"2022","journal-title":"Rev. da Assoc. Med. Bras. (1992)"},{"key":"10.1016\/j.critrevonc.2026.105214_bib55","article-title":"Long non-coding RNA STMN1P2 promotes breast cancer doxorubicin resistance by inhibiting pyroptosis through the hnRNPU-EZH2-TARF6-MALT1-caspase-1 pathway","author":"Jin","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib56","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1515\/biol-2020-0086","article-title":"LncRNA SNHG15 contributes to doxorubicin resistance of osteosarcoma cells through targeting the miR-381-3p\/GFRA1 axis","volume":"15","author":"Zhang","year":"2020","journal-title":"Open life Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105214_bib57","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/cbin.11889","article-title":"LncRNA FGD5-AS1 potentiates autophagy-associated doxorubicin resistance by regulating the miR-154-5p\/WNT5A axis in osteosarcoma","volume":"46","author":"Fei","year":"2022","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.critrevonc.2026.105214_bib58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2017.03.018","article-title":"Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2","volume":"396","author":"Zhang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105214_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2023.100512","article-title":"Long non-coding RNA PVT1 (PVT1) affects the expression of CCND1 and promotes doxorubicin resistance in osteosarcoma cells","volume":"43","author":"Li","year":"2023","journal-title":"J. Bone Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00280-016-3194-4","article-title":"Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma","volume":"79","author":"Zhang","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib61","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bbrc.2018.09.160","article-title":"Long noncoding RNA LOXL1-AS1 regulates prostate cancer cell proliferation and cell cycle progression through miR-541-3p and CCND1","volume":"505","author":"Long","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib62","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12951-020-00716-0","article-title":"Exosomal LncRNA-NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p","volume":"18","author":"Zhuang","year":"2020","journal-title":"J. nanobiotechnology"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib63","doi-asserted-by":"crossref","first-page":"11430","DOI":"10.1080\/21655979.2022.2063592","article-title":"LncRNA SNHG10 suppresses the development of doxorubicin resistance by downregulating miR-302b in triple-negative breast cancer","volume":"13","author":"Aini","year":"2022","journal-title":"Bioengineered"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105214_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1418","article-title":"LncRNA NEAT1 suppresses cellular senescence in hepatocellular carcinoma via KIF11-dependent repression of CDKN2A","volume":"13","author":"Chen","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib65","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/CAD.0000000000001393","article-title":"Long noncoding RNA TUG1 decreases bladder cancer chemo-sensitivity toward doxorubicin through elevating KPNA2 expression and activating the PI3K\/AKT pathway via adsorbing miR-582-5p","volume":"34","author":"Lu","year":"2023","journal-title":"AntiCancer Drugs"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105214_bib66","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1080\/15548627.2021.2007027","article-title":"CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma","volume":"18","author":"Yao","year":"2022","journal-title":"Autophagy"},{"issue":"488","key":"10.1016\/j.critrevonc.2026.105214_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0936","article-title":"Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state","volume":"11","author":"Echeverria","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105214_bib68","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00439-023-02610-9","article-title":"CRISPR\/Cas-based gene editing in therapeutic strategies for beta-thalassemia","volume":"142","author":"Zeng","year":"2023","journal-title":"Hum. Genet."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105214_bib69","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1080\/14760584.2022.2112952","article-title":"An overview: CRISPR\/Cas-based gene editing for viral vaccine development","volume":"21","author":"Bhujbal","year":"2022","journal-title":"Expert Rev. Vaccin."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/pbi.13490","article-title":"CRISPR\/Cas-based precision genome editing via microhomology-mediated end joining","volume":"19","author":"Van Vu","year":"2021","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.critrevonc.2026.105214_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2020.104558","article-title":"The critical roles of lncRNAs in the pathogenesis of melanoma","volume":"117","author":"Safa","year":"2020","journal-title":"Exp. Mol. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105214_bib72","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.14882","article-title":"Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma","volume":"179","author":"Handa","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105214_bib73","article-title":"Chemotherapeutic Risk lncRNA-PVT1 SNP Sensitizes Metastatic Colorectal Cancer to FOLFOX Regimen","volume":"12","author":"Wu","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib74","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/1381612826666200917150130","article-title":"Oncogenic LncRNA CASC9 in Cancer Progression","volume":"27","author":"Qi","year":"2021","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib75","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1186\/s12885-019-6021-6","article-title":"Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma","volume":"19","author":"Sassenberg","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib76","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.apsb.2020.10.001","article-title":"Long non-coding RNAs: From disease code to drug role","volume":"11","author":"Chen","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"54","key":"10.1016\/j.critrevonc.2026.105214_bib77","doi-asserted-by":"crossref","first-page":"91990","DOI":"10.18632\/oncotarget.21121","article-title":"LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105214_bib78","doi-asserted-by":"crossref","first-page":"13159","DOI":"10.2147\/OTT.S255113","article-title":"Interactions Between lncRNA TUG1 and miR-9-5p Modulate the Resistance of Breast Cancer Cells to Doxorubicin by Regulating eIF5A2","volume":"13","author":"Wang","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105214_bib79","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41419-021-04117-5","article-title":"Functional delivery of lncRNA TUG1 by endothelial progenitor cells derived extracellular vesicles confers anti-inflammatory macrophage polarization in sepsis via impairing miR-9-5p-targeted SIRT1 inhibition","volume":"12","author":"Ma","year":"2021","journal-title":"Cell death Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib80","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12890-021-01582-8","article-title":"XIST promotes apoptosis and the inflammatory response in CSE-stimulated cells via the miR-200c-3p\/EGR3 axis","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Pulm. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib81","first-page":"2257","article-title":"lncRNA NORAD promotes hepatocellular carcinoma progression via regulating miR-144-3p\/SEPT2","volume":"12","author":"Tian","year":"2020","journal-title":"Am. J. Transl. Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib82","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1536\/ihj.24-808","article-title":"Mechanism of LncRNA NORAD\/MiR-144-3p Axis in Promoting Myocardial Ischemia-Reperfusion Injury by Targeting TNRC6A","volume":"66","author":"Wei","year":"2025","journal-title":"Int. Heart J."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib83","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ncrna.2022.12.002","article-title":"lncRNA-mediated ceRNA network in bladder cancer","volume":"8","author":"Li","year":"2023","journal-title":"Noncoding RNA Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105214_bib84","article-title":"Pectin: A Bioactive Food Polysaccharide with Cancer Preventive Potential","volume":"27","author":"Emran","year":"2022","journal-title":"Mol. (Basel Switz. )"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105214_bib85","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/jmedgenet-2015-103334","article-title":"ceRNA in cancer: possible functions and clinical implications","volume":"52","author":"Qi","year":"2015","journal-title":"J. Med. Genet."},{"issue":"7483","key":"10.1016\/j.critrevonc.2026.105214_bib86","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature12986","article-title":"The multilayered complexity of ceRNA crosstalk and competition","volume":"505","author":"Tay","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib87","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/14737140.2020.1760095","article-title":"microRNAs as biomarkers of ovarian cancer","volume":"20","author":"Zhang","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib88","first-page":"435","article-title":"Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K\/AKT\/mTOR signaling pathway","volume":"18","author":"Li","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.critrevonc.2026.105214_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105195","article-title":"PI3K\/AKT\/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma","volume":"160","author":"Wu","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib90","first-page":"2311","article-title":"Long non\u2011coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K\/Akt\/mTOR pathway in acute myeloid leukaemia cells","volume":"41","author":"Yang","year":"2019","journal-title":"Oncol. Rep."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105214_bib91","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1161\/CIRCRESAHA.121.319104","article-title":"atg7-Based Autophagy Activation Reverses Doxorubicin-Induced Cardiotoxicity","volume":"129","author":"Wang","year":"2021","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0000000000000572","article-title":"Autophagy and doxorubicin resistance in cancer","volume":"29","author":"Chen","year":"2018","journal-title":"AntiCancer Drugs"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib93","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.17956","article-title":"LncRNA SNHG15 regulates autophagy and prevents cerebral ischaemia-reperfusion injury through mediating miR-153-3p\/ATG5 axis","volume":"28","author":"Yu","year":"2024","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib94","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/15476286.2022.2079889","article-title":"DARS-AS1 recruits METTL3\/METTL14 to bind and enhance DARS mRNA m(6)A modification and translation for cytoprotective autophagy in cervical cancer","volume":"19","author":"Shen","year":"2022","journal-title":"RNA Biol."},{"key":"10.1016\/j.critrevonc.2026.105214_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126147","article-title":"CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy","volume":"250","author":"Liu","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib96","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1038\/s41467-023-43974-w","article-title":"LncRNA MIR200CHG inhibits EMT in gastric cancer by stabilizing miR-200c from target-directed miRNA degradation","volume":"14","author":"Zhu","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib97","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2741\/4472","article-title":"MALAT1-mediated tumorigenesis","volume":"22","author":"Liu","year":"2017","journal-title":"Front. Biosci. (Landmark Ed. )"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105214_bib98","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/15384047.2020.1794239","article-title":"Long non-coding RNA (lncRNA) and epithelial-mesenchymal transition (EMT) in colorectal cancer: a systematic review","volume":"21","author":"O'Brien","year":"2020","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib99","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4274\/balkanmedj.galenos.2024.2024-8-49","article-title":"Matrine Inhibits Breast Cancer Cell Proliferation and Epithelial-Mesenchymal Transition Through Regulating the LINC01116\/miR-9-5p\/ITGB1 Axis","volume":"42","author":"Ren","year":"2025","journal-title":"Balk. Med. J."},{"issue":"34","key":"10.1016\/j.critrevonc.2026.105214_bib100","article-title":"M(6)A-mediated upregulation of lncRNA TUG1 in liver cancer cells regulates the antitumor response of CD8(+) T cells and phagocytosis of macrophages","volume":"11","author":"Xi","year":"2024","journal-title":"Advanced science (Weinheim BadenWurttemberg Germany)"},{"key":"10.1016\/j.critrevonc.2026.105214_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2025.110492","article-title":"The m6A transferase METTL3 regulates high glucose-induced proliferation and apoptosis of human lens epithelial cells through the lncRNA TUG1\/KHSRP\/p38MAPK signaling axis","volume":"258","author":"Li","year":"2025","journal-title":"Exp. eye Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105214_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/cells11213436","article-title":"Cuprotosis Programmed-Cell-Death-Related lncRNA Signature Predicts Prognosis and Immune Landscape in PAAD Patients","volume":"11","author":"Chi","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib103","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s10020-022-00551-z","article-title":"LncRNA FENDRR with m6A RNA methylation regulates hypoxia-induced pulmonary artery endothelial cell pyroptosis by mediating DRP1 DNA methylation","volume":"28","author":"Wang","year":"2022","journal-title":"Mol. Med. (Camb. Mass)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib104","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41419-021-04484-z","article-title":"METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA","volume":"13","author":"Meng","year":"2022","journal-title":"Cell death Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s43018-023-00695-9","article-title":"LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells","volume":"5","author":"Kumar","year":"2024","journal-title":"Nat. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib106","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105214_bib107","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.molcel.2022.03.022","article-title":"Ferroptosis at the intersection of lipid metabolism and cellular signaling","volume":"82","author":"Liang","year":"2022","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","article-title":"Ferroptosis: molecular mechanisms and health implications","volume":"31","author":"Tang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.critrevonc.2026.105214_bib109","first-page":"23","article-title":"Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19\/miR-19b-3p\/FTH1 axis","volume":"13","author":"Zhang","year":"2022","journal-title":"Bioact. Mater."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.32604\/or.2023.027815","article-title":"LncRNA CACNA1G-AS1 up-regulates FTH1 to inhibit ferroptosis and promote malignant phenotypes in ovarian cancer cells","volume":"31","author":"Jin","year":"2023","journal-title":"Oncol. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105214_bib111","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1300","article-title":"Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation","volume":"13","author":"Shi","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105214_bib112","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41419-022-05173-1","article-title":"LncRNA HEPFAL accelerates ferroptosis in hepatocellular carcinoma by regulating SLC7A11 ubiquitination","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell death Dis."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib113","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105214_bib114","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cbin.11137","article-title":"Cell death: a review of the major forms of apoptosis, necrosis and autophagy","volume":"43","author":"D'Arcy","year":"2019","journal-title":"Cell Biol. Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib115","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180992","article-title":"Apoptosis and apoptotic body: disease message and therapeutic target potentials","volume":"39","author":"Xu","year":"2019","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib116","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-023-01925-5","article-title":"Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy","volume":"23","author":"Chehelgerdi","year":"2024","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105214_bib118","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41580-023-00697-6","article-title":"CRISPR technologies for genome, epigenome and transcriptome editing","volume":"25","author":"Villiger","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70151-w","article-title":"LncRNA GHET1 from bone mesenchymal stem cell-derived exosomes improves doxorubicin-induced pyroptosis of cardiomyocytes by mediating NLRP3","volume":"14","author":"Zhai","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105214_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2019.101490","article-title":"lncRNA PVT1 aggravates doxorubicin-induced cardiomyocyte apoptosis by targeting the miR-187-3p\/AGO1 axis","volume":"49","author":"Zhan","year":"2020","journal-title":"Mol. Cell. probes"},{"key":"10.1016\/j.critrevonc.2026.105214_bib121","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.canlet.2018.01.008","article-title":"Membrane-lipid associated lncRNA: A new regulator in cancer signaling","volume":"419","author":"Ma","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105214_bib122","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cca.2018.07.004","article-title":"LncRNA HOXA-AS2 and its molecular mechanisms in human cancer","volume":"485","author":"Wang","year":"2018","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105214_bib123","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.prp.2018.04.003","article-title":"LncRNA-DANCR: A valuable cancer related long non-coding RNA for human cancers","volume":"214","author":"Thin","year":"2018","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib124","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/cbdd.14006","article-title":"Multiple function of lncRNA MALAT1 in cancer occurrence and progression","volume":"101","author":"Malakoti","year":"2023","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100365","article-title":"Targeting immunoliposomes to EGFR-positive glioblastoma","volume":"7","author":"Kasenda","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105214_bib126","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2147\/IJN.S131418","article-title":"EGFR-targeted delivery of DOX-loaded Fe(3)O(4)@ polydopamine multifunctional nanocomposites for MRI and antitumor chemo-photothermal therapy","volume":"12","author":"Mu","year":"2017","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib127","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10238-024-01355-7","article-title":"Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors","volume":"24","author":"Fu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105214_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of Lipid Nanoparticles for RNA Delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105214_bib130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/1389200221666200508074348","article-title":"Polymeric Nanoparticles for Brain Drug Delivery - A Review","volume":"21","author":"Raman","year":"2020","journal-title":"Curr. Drug Metab."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105214_bib131","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric Nanoparticles for Drug Delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105214_bib132","article-title":"Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology","volume":"25","author":"Zieli\u0144ska","year":"2020","journal-title":"Mol. (Basel Switz. )"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113050","article-title":"LncRNA ODRUL regulates progression of osteosarcoma by regulating IL-6 via sponging miR-6874-3p","volume":"412","author":"Zhan","year":"2022","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib134","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.drudis.2021.09.020","article-title":"Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects","volume":"27","author":"Mirzaei","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2026.105214_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112967","article-title":"Chemotherapy-mediated lncRNA-induced immune cell plasticity in cancer immunopathogenesis","volume":"141","author":"Lu","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"Pt B","key":"10.1016\/j.critrevonc.2026.105214_bib136","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ijbiomac.2022.09.209","article-title":"Interactome battling of lncRNA CCDC144NL-AS1: Its role in the emergence and ferocity of cancer and beyond","volume":"222","author":"Abd El Fattah","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"33","key":"10.1016\/j.critrevonc.2026.105214_bib137","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030045","article-title":"Role of noncoding RNAs and untranslated regions in cancer: A review","volume":"101","author":"Zhang","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.critrevonc.2026.105214_bib138","article-title":"5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1\/SLC7A11-mediated ferroptosis","volume":"78","author":"Shi","year":"2025","journal-title":"Drug Resist. Update. Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"10.1016\/j.critrevonc.2026.105214_bib139","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.biopha.2018.03.105","article-title":"Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma","volume":"102","author":"Toraih","year":"2018","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105214_bib140","first-page":"4024","article-title":"Long non-coding RNA CASC9 knockdown inhibits the progression of nasopharyngeal carcinoma by regulating miR-145","volume":"12","author":"Liu","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib141","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13018-022-03181-7","article-title":"EBF1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p\/G3BP2 axis as a ceRNA","volume":"17","author":"Shuang","year":"2022","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.critrevonc.2026.105214_bib142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-981-13-0502-3_4","article-title":"High Throughput Single Cell RNA Sequencing, Bioinformatics Analysis and Applications","volume":"1068","author":"Huang","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105214_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218345","article-title":"Review of Single-Cell RNA Sequencing in the Heart","volume":"21","author":"Yamada","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105214_bib144","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41576-019-0150-2","article-title":"RNA sequencing: the teenage years","volume":"20","author":"Stark","year":"2019","journal-title":"Nat. Rev. Genet."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105214_bib145","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70103","article-title":"Ginsenoside Rg1 Regulates the Activation of Astrocytes Through lncRNA-Malat1\/miR-124-3p\/Lamc1 Axis Driving PI3K\/AKT Signaling Pathway, Promoting the Repair of Spinal Cord Injury","volume":"30","author":"Zhu","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105214_bib146","first-page":"7653","article-title":"MALAT1 promotes cisplatin resistance in cervical cancer by activating the PI3K\/AKT pathway","volume":"22","author":"Wang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib147","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur. J. Dermatol. EJD"},{"key":"10.1016\/j.critrevonc.2026.105214_bib148","article-title":"1990-2019: an update from the Global Burden of Disease Study 2019","volume":"59","author":"Global burden of chronic respiratory diseases and risk factors","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105214_bib149","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.2015.13183","article-title":"Benefits and Harms of Breast Cancer Screening: A Systematic Review","volume":"314","author":"Myers","year":"2015","journal-title":"Jama"},{"key":"10.1016\/j.critrevonc.2026.105214_bib150","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","article-title":"Lipid nanoparticles for siRNA delivery in cancer treatment","volume":"361","author":"El Moukhtari","year":"2023","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105214_bib151","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","article-title":"Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects","volume":"20","author":"Kon","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"51","key":"10.1016\/j.critrevonc.2026.105214_bib152","article-title":"Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv. Mater. (Deerfield Beach Fla)"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105214_bib153","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bcp.12267","article-title":"Paediatric pharmacokinetics: key considerations","volume":"79","author":"Batchelor","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib154","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.critrevonc.2026.105214_bib155","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1146\/annurev-immunol-042718-041522","article-title":"CRISPR-Based Tools in Immunity","volume":"37","author":"Simeonov","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105214_bib156","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymben.2020.10.004","article-title":"CRISPR-based metabolic pathway engineering","volume":"63","author":"Zhao","year":"2021","journal-title":"Metab. Eng."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105214_bib157","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41573-023-00762-x","article-title":"Drug delivery systems for CRISPR-based genome editors","volume":"22","author":"Madigan","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib158","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2023000472","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib159","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaci.2024.08.030","article-title":"Serum cytokine panels in pediatric clinical practice","volume":"155","author":"Gallo","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105214_bib160","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246324","article-title":"miRNA- and lncRNA-Based Therapeutics for Non-Hodgkin's Lymphoma: Moving towards an RNA-Guided Precision Medicine","volume":"13","author":"Fernandes","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105214_bib161","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics - challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib162","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105214_bib163","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/gm477","article-title":"Circulating tumor cells and DNA as liquid biopsies","volume":"5","author":"Heitzer","year":"2013","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib164","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13048-017-0369-5","article-title":"Circulating cell-free DNA and circulating tumor cells, the \"liquid biopsies\" in ovarian cancer","volume":"10","author":"Cheng","year":"2017","journal-title":"J. ovarian Res."},{"issue":"695","key":"10.1016\/j.critrevonc.2026.105214_bib165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf6724","article-title":"Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies","volume":"15","author":"Shi","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105214_bib166","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2013.218","article-title":"Biomarker enrichment strategies: matching trial design to biomarker credentials","volume":"11","author":"Freidlin","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105214_bib167","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10147-024-02525-z","article-title":"Biomarker-oriented chemo-immunotherapy for advanced gastric cancer","volume":"29","author":"Kono","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105214_bib168","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of antisense oligonucleotide and siRNA-based therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib169","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105214_bib170","article-title":"Optimizing Lipid Nanoparticles for Delivery in Primates","volume":"35","author":"Lam","year":"2023","journal-title":"Adv. Mater. (Deerfield Beach Fla)"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105214_bib171","article-title":"Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy","volume":"27","author":"Wang","year":"2022","journal-title":"Mol. (Basel Switz. )"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105214_bib172","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.7150\/ijbs.112133","article-title":"MALAT1 promotes malignancy of HBV-related hepatocellular carcinoma by regulating IGF2BP3-mediated nuclear-cytoplasmic shuttling","volume":"21","author":"Du","year":"2025","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105214_bib173","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.joim.2024.11.003","article-title":"Resveratrol promotes mitophagy via the MALAT1\/miR-143-3p\/RRM2 axis and suppresses cancer progression in hepatocellular carcinoma","volume":"23","author":"Feng","year":"2025","journal-title":"J. Integr. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105214_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100774","article-title":"Cancer Susceptibility Candidate 9 (CASC9): A Novel Targetable Long Noncoding RNA in Cancer Treatment","volume":"13","author":"Sharma","year":"2020","journal-title":"Transl. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105214_bib175","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.critrevonc.2026.105214_bib176","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2018.08.005","article-title":"Aptamer-based targeted therapy","volume":"134","author":"Zhu","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105214_bib177","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105214_bib178","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174232","article-title":"Novel Insights into miR-944 in Cancer","volume":"14","author":"Shen","year":"2022","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105214_bib179","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","article-title":"A pan-cancer single-cell panorama of human natural killer cells","volume":"186","author":"Tang","year":"2023","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105214_bib180","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cell.2023.01.002","article-title":"Bacterial droplet-based single-cell RNA-seq reveals antibiotic-associated heterogeneous cellular states","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"issue":"8019","key":"10.1016\/j.critrevonc.2026.105214_bib181","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41586-024-07517-7","article-title":"Single-cell nascent RNA sequencing unveils coordinated global transcription","volume":"631","author":"Mahat","year":"2024","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105214_bib182","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/tox.23551","article-title":"Long noncoding RNA TDRG1 aggravates doxorubicin-induced cardiomyopathy by binding with miR-873-5p to upregulate PRKAR2","volume":"37","author":"Liu","year":"2022","journal-title":"Environ. Toxicol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105214_bib183","article-title":"Long Non-Coding RNA, Apoptosis, and Doxorubicin-Induced Cardiotoxicity","volume":"121","author":"Tonon","year":"2024","journal-title":"Arq. Bras. De. Cardiol."},{"key":"10.1016\/j.critrevonc.2026.105214_bib184","article-title":"Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management","volume":"139","author":"Rawat","year":"2021","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105214_bib185","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1039\/C6TB03038F","article-title":"HDAC Inhibitor Conjugated Polymeric Prodrug Micelles for Doxorubicin Delivery","volume":"5","author":"Senevirathne","year":"2017","journal-title":"J. Mater. Chem. B"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105214_bib186","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10549-019-05504-5","article-title":"Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously","volume":"179","author":"Hii","year":"2020","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:46:00Z","timestamp":1775907960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":186,"alternative-id":["S1040842826001010"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105214","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting lncRNA-mediated networks to overcome doxorubicin resistance in cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105214"}}